NCT03571763 The Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients
| NCT ID | NCT03571763 |
| Status | Recruiting |
| Phase | — |
| Sponsor | General Hospital of Shenyang Military Region |
| Condition | Ischemic Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,875 participants |
| Start Date | 2018-08-01 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,875 participants in total. It began in 2018-08-01 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this prospective cohort study is to investigate whether antithrombotic therapy in the secondary prevention of ischemic stroke increases the risk of the emerging CMBs and whether the change is associated with an increased risk of intracranial hemorrhage, providing an imaging evidence for individualized antithrombotic therapy in such patients.
Eligibility Criteria
Inclusion Criteria: 1. Patient age ≥18 years; 2. Acute ischemic stroke patient confirmed by imaging; 3. Time of onset: within 3 months; 4. Baseline SWI sequence is completed before starting the secondary prevention of ischemic stroke; 5. Baseline SWI sequence must have at least one CMB ; 6. NIHSS≤10 Exclusion Criteria: 1. MRI contraindication; 2. Hemorrhagic transformation after acute Ischemic stroke; 3. Contraindication for antiplatelet or anticoagulation therapy; 4. Severe head trauma or intracranial hemorrhage occurred in the past six months; 5. obvious coagulopathy; 6. Other intracranial lesions associated with (such as tumor, cerebral vascular malformation); 7. other unqualified patients judged by the investigator
Contact & Investigator
chen huisheng, doctor
STUDY DIRECTOR
General Hospital of Shenyang Military Region
Frequently Asked Questions
Who can join the NCT03571763 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03571763 currently recruiting?
Yes, NCT03571763 is actively recruiting participants. Contact the research team at chszh@aliyun.com for enrollment information.
Where is the NCT03571763 trial being conducted?
This trial is being conducted at Shenyang, China.
Who is sponsoring the NCT03571763 clinical trial?
NCT03571763 is sponsored by General Hospital of Shenyang Military Region. The principal investigator is chen huisheng, doctor at General Hospital of Shenyang Military Region. The trial plans to enroll 1,875 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.